Physician profile
Michael Mcintosh
NPI 1609934777
$1,356.70
in general payments reported to CMS, 2019-2025
9 companies · $205 in 2025
The $205 reported for 2025 was more than what a typical Child & Adolescent Psychiatry provider received nationally (typical 2025 total: $132).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $56.90 · 2021: $48.97 · 2022: $257 · 2023: $298 · 2024: $491 · 2025: $205.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $945 · Education: $48.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $944.56 |
| Education | $48.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $387.68 | 2022-2025 | Caplyta |
| Axsome Therapeutics, INC. | $331.98 | 2022-2025 | Auvelity |
| Tris Pharma INC | $269.89 | 2022-2024 | Dyanavel Xr |
| Sunovion Pharmaceuticals INC. | $193.67 | 2019-2022 | |
| Ironshore Pharmaceuticals INC. | $47.38 | 2019-2023 | Jornay Pm |
| Otsuka America Pharmaceutical, INC. | $41.44 | 2022-2024 | Rexulti |
| Neos Therapeutics, Lp | $31.42 | 2023-2024 | Adzenys Xr-Odt |
| Supernus Pharmaceuticals, INC. | $27.81 | 2024 | Qelbree |
| Vanda Pharmaceuticals INC. | $25.43 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Mcintosh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.